Komen Debuts New Websites on Breast Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 12
Volume 6
Issue 12

DALLAS-The Susan G. Komen Breast Cancer Foundation, known for raising awareness and community support for breast cancer research and programs through its Race for the Cure, has unveiled three new websites that form a comprehensive online source of breast health and breast cancer information.

DALLAS—The Susan G. Komen Breast Cancer Foundation, known for raising awareness and community support for breast cancer research and programs through its Race for the Cure, has unveiled three new websites that form a comprehensive online source of breast health and breast cancer information.

“We’ve developed a sound source of trusted information that can be tapped into anytime, day or night,” said Nancy Brinker, founding chairman of the Komen Foundation. “And we’ve gone a step further by providing people the ability to share their personal experiences on our websites, creating a sense of empowerment and community spirit online.”

Internet users can access the websites by using one of three Internet addresses: (1) www.breastcancerinfo.com, (2) www.raceforthecure.com, and (3) www.komen.org. Once logged on to any of the three sites, a toolbar allows easy access to the information on all three.

The site includes more than 100 pages of breast health information, areas designed for breast cancer survivors and their families, information on the Race for the Cure, and a calendar of breast cancer-related events and programs. Researchers can use the site to access applications for Komen Foundation grants.

A series of “Talk Back” sections encourage visitor participation and involvement by allowing users to share their first-hand experience with breast cancer.

Funds raised through the Lee National Denim Day in 1996 helped underwrite the website. The Lee Company invites corporations to participate by allowing their employees to wear denim to work on that day in exchange for a $5 contribution to the Komen Foundation.

Recent Videos
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Related Content